[Business Wire] – Bristol-Myers Squibb Company and Pfizer Inc. today announced the results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis compared to warfarin according to blood pressure control.1 The results showed that poor blood pressure control was associated with a substantially higher risk of …
Read more on this.
Bristol-Myers Squibb Company (BMY), with a current value of $85.73B, started the session at $52.49.
Shares have traded today between $51.51 and $52.57 per share with a trailing 52-week range being $39.18 to $57.49.
Bristol-Myers Squibb (BMY) shares are currently priced at 28.67x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.27x earnings multiple for the same period.
And for those looking to make a return holding the stock, the company pays shareholders $1.44 per share annually in dividends, yielding 2.80%.
In a review of the consensus earnings estimate this quarter, 15 sell-side analysts are looking at $0.45 per share, which would be $0.04 better than the year-ago quarter and a $0.01 sequential increase. Investors should also note that the full-year EPS estimate of $1.78 is a $0.04 setback when compared to the previous year’s annual results.
The quarterly earnings estimate is predicated on a consensus revenue forecast of $4.00 Billion. If reported, that would be a 4.44% increase over the year-ago quarter.
Recently, Barclays upgraded BMY from Equal Weight to Overweight (Jan 10, 2014). Previously, Jefferies downgraded BMY from Buy to Hold.
With the above information in mind, readers should note that the average price target is $55.12, which is 5.01% above where the stock opened this morning.
Summary (NYSE:BMY) : Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The companys principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Tag Helper ~ Stock Code: BMY | Common Company name: Bristol-Myers Squibb | Full Company name: Bristol-Myers Squibb Company (NYSE:BMY) .